Skip to content

Forte Bio up on positive FB-401 data in atopic dermatitis

September 10, 2020

Forte Biosciences (NASDAQ:FBRX) announces full results of Phase 1/2a trial of lead product candidate, FB-401 in atopic dermatitis (AD) patients in Science Translational Medicine.

In the pediatric cohort, 20 AD patients of age from 3 to 16 years of age, were treated topically with FB-401 for 16 weeks.

90% (18/20) of the pediatric patients reported at least a 50% improvement in the Eczema Activity and Severity Index (EASI-50) with 100% (9/9) of the moderate-to-severe patients achieving EASI-50.

The mean improvement in the EASI score was 77% with development observed on all actively treated body sites. Pruritus (itch) also improved by an average 58%.

The mechanism of action for FB-401 involves pathways that drive tissue repair and anti-inflammation.

Overall, FB-401 demonstrated excellent tolerability and significant improvement in disease activity in both adults and children.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: